Non-invasive Evaluation of Lymphoma Patients Based on Artificial Intelligence and PET/MRI

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04154228

Enrollment

100

Registered

2019-11-06

Start date

2019-12-10

Completion date

2021-12-10

Last updated

2019-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Follicular Lymphoma, Lymphoma, Non Hodgkin Lymphoma

Keywords

Lymphoma, Non Hodgkin Lymphoma, Follicular Lymphoma

Brief summary

18F-FDG PET/MR imaging protocol integrating advanced MR vascular imaging sequences, along with computerized quantitative methods for data analysis, is expected to serve as an objective tool for assessment of lymphoma patients. The aim of this prospective study is to develop an automatic artificial intelligence-based tool for the assessment of early response to treatment and evaluation of residual masses in patients with lymphoma. Specific objectives are: 1. To evaluate the added value of 18F-FDG PET/MRI compared with PET/CT in imaging lymphoma. 2. To optimize PET/MR imaging protocol for lymphoma assessment. 3. To develop an automated tool for staging patients with lymphoma. 4. To develop an automated method for early prediction of response to therapy and prognosis in patients with lymphoma. 5. To develop an automated non-invasive tool for discriminating benign from active residual masses at end of treatment in patients with lymphoma.

Interventions

DIAGNOSTIC_TESTPET/MR scan

Patients will undergo 18F-FDG PET/CT scans before therapy initiation, interim after 2/3 treatment cycles and end of treatment after therapy completion, as part of their routine evaluation, as well as additional follow-up scans, as clinically indicated and requested by referring physicians. Given signed written informed-consent forms, patients will undergo at each time point, immediately after completion of PET/CT, a PET/MR scan, following the same single injection of 18F-FDG. Standard preparation and acquisition protocols for FDG PET imaging will be employed. PET/MR imaging will include conventional sequences as T1, T2, diffusion weighted imaging, and advanced vascular imaging (DCE-MRI).

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 120 Years

Healthy volunteers

Inclusion criteria

1. patients with newly diagnosed hodgkin's, aggressive non-hodgkin's and follicular lymphoma (for whom the PET/CT is the imaging modality of choice)/ 2. Patients aged 18 years or older of both sexes. 3. Patients treated at Tel-Aviv Sourasky Medical center.

Exclusion criteria

1. pregnancy, 2. contraindication to MRI or to intravenous gadolinium injection.

Design outcomes

Primary

Measure	Time frame	Description
Patients that preform 18F-FDG PET/MRI and the routinely PET/CT	1 year	Patients that preform 18F-FDG PET/MRI and the routinely PET/CT, and the investigators optimize PET/MRI imaging protocol, and to develop an automated artificial intelligence-based tool for assessment of early response to treatment in patients with lymphoma.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026